The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Anti-PCSK9 antibodies are the jewel in the crown of modern genomic medicine, illustrating what many hope will be a paradigm for future drug discovery.

For whichever PCSK9 we choose, we get an additional 50% to 60% LDL reduction by using these therapies. So, they work. They lower events. Both trials with PCSK9 inhibitors lowered events by about 15%.

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

The PCSK9 inhibitors pose a similar, but in many ways more compelling and complex, set of problems. Their target, hyperlipidemia, is one of the most prevalent conditions in the developed world.

PCSK9’s story begins a dozen years ago when researchers led by Nabil G. Seidah of the Clinical Research Institute of Montreal discovered an unusual protein (Proc. Natl. Acad. Sci. USA 2003, DOI ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

Compared with placebo, PCSK9 inhibition carried a lower rate of death or intubation in the first 30 days (23.3% vs 53.3%), with numerical reductions in both of the individual components of that ...

Therefore, "PCSK9 inhibition may represent a novel therapeutic pathway in addition to currently recommended therapeutic approaches for severe COVID-19," conclude the authors, led by Eliano P ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year ...